CIPLA: The Chemical, Industrial & Pharmaceutical Laboratories
Wednesday, 6th June, 2007
“There’ll always be a healthier way to live, a warmer way to care, a surer way to heal, a calmer way to sleep. There’ll always be a better world, for those who have the passion to create it”, that’s been Cipla’s belief since 1935.A small Indian enterprise committed to the nation’s quest for self-sufficiency, Cipla rose to the challenge of meeting the alarming shortage of essential medicines. It was Cipla only which truly laid the foundation of the Pharmaceutical industry in India when it pioneered Bulk Drug manufacturing in the country in 1960’s decade.
With 31 world class manufacturing facilities spread across the country. Cipla has dedicated plants for different segments like products for Oncology, harmones, inhalers, Carbapenems and cephlosporins etc. The best thing to acknowledge is the standard of the products which meets the stringent international standards, such as that of US FDA, MHRA–UK, TGA Australia, BFarm–Germany MCC–South Africa, WHO, TPD- Canada.
Cipla produces one of the widest range of products and dosage forms in the world today, everything from metered-dose inhalers, pre-filled syringes, trans-dermal spray patches, lyophilized injections, nasal sprays, medical devices, and thermolabile foams. Whether it is constantly extending our product range or consistently introducing innovations, the mission is always to make the life of the patient better.
Cipla products are bought by over 170 countries located in the following regions:
Cipla is also the only Indian company opposing Gilead’s patent application for its blockbuster anti-HIV drug Viread in India.
The company was founded in 1935 by Khwaja Abdul Hamied, and its chairman today is Yusuf Hamied.
In financial terms, Exports for the financial year ended March 31, 2007 amounted to more than Rs. 17,800 million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla also offers technology for products and processes. Technical know-how/fees received during the year 2006-07 amounted to Rs. 764.70 million.
Today (2007), Cipla is the world’s largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed (multinational brand-name drugs are much more expensive, so in money terms Cipla’s medicines are probably not in top spot). At least 40% of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs.
